| $687M | ||
| $385M | ||
| $215M | ||
| $100M | ||
| $87M | ||
| $82M |
Buys | $69,600 | 1 | 4 |
Sells | $1,999,856 | 24 | 96 |
| LINDSTROM RICHARD L MD | director | 1 | $69,600 | 0 | $0 | $69,600 |
| Nayak Sanjay | Chief Strategy Officer | 0 | $0 | 4 | $71,619 | $-71,619 |
| Waheed Nadia | Chief Medical Officer | 0 | $0 | 1 | $111,581 | $-111,581 |
| Anderman Todd | Chief Legal Officer | 0 | $0 | 1 | $137,369 | $-137,369 |
| Notman Donald | See Remarks | 0 | $0 | 3 | $149,490 | $-149,490 |
| Kaiser Peter | Chief Development Officer | 0 | $0 | 5 | $220,865 | $-220,865 |
| Heier Jeffrey S. | Chief Scientific Officer | 0 | $0 | 5 | $237,329 | $-237,329 |
| Saroj Namrata | Chief Business Officer | 0 | $0 | 1 | $277,790 | $-277,790 |
| Dugel Pravin | See Remarks | 0 | $0 | 4 | $793,815 | $-793,815 |
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Over the last 12 months, insiders at Ocular Therapeutix, Inc. have bought $69,600 and sold $2M worth of Ocular Therapeutix, Inc. stock.
On average, over the past 5 years, insiders at Ocular Therapeutix, Inc. have bought $2.84M and sold $842,367 worth of stock each year.
Highest buying activity among insiders over the last 12 months: LINDSTROM RICHARD L MD (director) — $69,600.
The last purchase of 10,000 shares for transaction amount of $69,600 was made by LINDSTROM RICHARD L MD (director) on 2025‑05‑08.
| 2025-11-24 | Sale | Dugel Pravin | See Remarks | 19,530 0.0111% | $12.04 | $235,141 | +4.95% | |
| 2025-11-24 | Sale | Nayak Sanjay | Chief Strategy Officer | 1,878 0.0011% | $12.04 | $22,611 | +4.95% | |
| 2025-11-24 | Sale | Heier Jeffrey S. | Chief Scientific Officer | 3,469 0.002% | $12.04 | $41,767 | +4.95% | |
| 2025-11-24 | Sale | Kaiser Peter | Chief Development Officer | 3,007 0.0017% | $12.02 | $36,144 | +4.95% | |
| 2025-11-05 | Sale | Saroj Namrata | Chief Business Officer | 25,865 0.0137% | $10.74 | $277,790 | +9.99% | |
| 2025-10-08 | Sale | Anderman Todd | Chief Legal Officer | 11,132 0.0066% | $12.34 | $137,369 | -1.18% | |
| 2025-10-02 | Sale | Heier Jeffrey S. | Chief Scientific Officer | 10,502 0.0057% | $11.04 | $115,942 | +6.33% | |
| 2025-10-02 | Sale | Kaiser Peter | Chief Development Officer | 9,653 0.0052% | $11.03 | $106,473 | +6.33% | |
| 2025-09-02 | Sale | Notman Donald | See Remarks | 1,066 0.0006% | $12.43 | $13,250 | -6.22% | |
| 2025-08-25 | Sale | Dugel Pravin | See Remarks | 21,494 0.0121% | $12.04 | $258,788 | +0.59% | |
| 2025-08-25 | Sale | Nayak Sanjay | Chief Strategy Officer | 1,885 0.0011% | $12.04 | $22,695 | +0.59% | |
| 2025-08-25 | Sale | Heier Jeffrey S. | Chief Scientific Officer | 3,063 0.0017% | $12.04 | $36,879 | +0.59% | |
| 2025-08-25 | Sale | Kaiser Peter | Chief Development Officer | 3,011 0.0017% | $12.04 | $36,252 | +0.59% | |
| 2025-06-02 | Sale | Waheed Nadia | Chief Medical Officer | 13,861 0.0086% | $8.05 | $111,581 | +45.50% | |
| 2025-05-23 | Sale | Dugel Pravin | See Remarks | 21,219 0.0131% | $7.18 | $152,352 | +61.10% | |
| 2025-05-23 | Sale | Nayak Sanjay | Chief Strategy Officer | 1,862 0.0011% | $7.17 | $13,351 | +61.10% | |
| 2025-05-23 | Sale | Heier Jeffrey S. | Chief Scientific Officer | 3,024 0.0019% | $7.18 | $21,712 | +61.10% | |
| 2025-05-23 | Sale | Kaiser Peter | Chief Development Officer | 2,974 0.0018% | $7.17 | $21,324 | +61.10% | |
| 2025-05-08 | LINDSTROM RICHARD L MD | director | 10,000 0.0059% | $6.96 | $69,600 | +56.71% | ||
| 2025-02-24 | Sale | Dugel Pravin | See Remarks | 21,475 0.0134% | $6.87 | $147,533 | +64.49% |
| Dugel Pravin | See Remarks | 3157960 1.8172% | $44.75M | 0 | 7 | |
| Notman Donald | See Remarks | 308807 0.1777% | $4.38M | 3 | 6 | +9.75% |
| Nayak Sanjay | Chief Strategy Officer | 277860 0.1599% | $3.94M | 0 | 7 | |
| Heier Jeffrey S. | Chief Scientific Officer | 245940 0.1415% | $3.48M | 2 | 6 | +22.62% |
| Waheed Nadia | Chief Medical Officer | 206805 0.119% | $2.93M | 0 | 1 | |
| Kaiser Peter | Chief Development Officer | 191433 0.1102% | $2.71M | 0 | 6 | |
| Saroj Namrata | Chief Business Officer | 174135 0.1002% | $2.47M | 0 | 1 | |
| LINDSTROM RICHARD L MD | director | 172704 0.0994% | $2.45M | 2 | 1 | <0.0001% |
| Anderman Todd | Chief Legal Officer | 87568 0.0504% | $1.24M | 0 | 1 | |
| SUMMER ROAD LLC | 10 percent owner | 8591401 4.9439% | $121.74M | 31 | 0 | +18.95% |
| Opaleye Management Inc. | 10 percent owner | 4918500 2.8303% | $69.7M | 2 | 0 | +99.18% |
| CHV II, L.P. | 10 percent owner | 2100138 1.2085% | $29.76M | 1 | 0 | +69.82% |
| Sawhney Amarpreet | Chairman of the Board | 1056031 0.6077% | $14.96M | 10 | 0 | +25.15% |
| Mattessich Antony C. | President and CEO | 588701 0.3388% | $8.34M | 6 | 3 | +7.2% |
| Strassburger Philip C. | General Counsel | 161493 0.0929% | $2.29M | 0 | 3 | |
| Ozden Rabia Gurses | Chief Medical Officer | 153054 0.0881% | $2.17M | 0 | 4 | |
| White Christopher G | Chief Business Officer | 123689 0.0712% | $1.75M | 0 | 3 | |
| Fortune James | Chief Operating Officer | 112060 0.0645% | $1.59M | 0 | 1 | |
| Ankerud Eric | See Remarks | 78651 0.0453% | $1.11M | 1 | 0 | +69.82% |
| SVLSF IV, LLC | 10 percent owner | 61084 0.0352% | $865,560.28 | 1 | 1 | +69.82% |
| Bollag Daniel M | See Remarks | 42100 0.0242% | $596,557.00 | 2 | 0 | +12.45% |
| Goldstein Michael H. | Chief Medical Officer | 25686 0.0148% | $363,970.62 | 2 | 0 | +41.08% |
| Hanley Kevin F. | See Remarks | 20000 0.0115% | $283,400.00 | 2 | 0 | <0.0001% |
| Polaris Venture Management Co. V, L.L.C. | 10 percent owner | 13419 0.0077% | $190,147.23 | 0 | 1 | |
| Warden Charles M | 13007 0.0075% | $184,309.19 | 0 | 2 | ||
| Versant Venture Capital III, L.P. | 10 percent owner | 13007 0.0075% | $184,309.19 | 0 | 2 | |
| Williams Leslie J. | director | 4500 0.0026% | $63,765.00 | 1 | 0 | +3.43% |
| PEACOCK BRUCE | director | 0 0% | $0 | 0 | 1 |
Ocular Therapeutix, Inc. (OCUL) | $54,590,806 | 65 | 21.84% | $2.46B |
$47,419,530 | 58 | 17.20% | $2.11B | |
$104,428,685 | 44 | 22.55% | $2.92B | |
$571,084,134 | 44 | 4.33% | $2.36B | |
$62,927,079 | 29 | 14.02% | $2.68B | |
$25,045,414 | 23 | -3.79% | $2.91B | |
$7,033,101 | 22 | -12.19% | $2.08B | |
$7,549,896 | 18 | 21.49% | $2.07B | |
$73,814,940 | 15 | -4.77% | $2.68B | |
$92,580,864 | 14 | -1.28% | $2.54B | |
$138,099,519 | 11 | 2.58% | $2.46B | |
$45,445,266 | 9 | -24.96% | $2.93B | |
$55,713,031 | 8 | -0.36% | $2.17B | |
$130,038,539 | 8 | 26.82% | $2.64B | |
$25,073,947 | 7 | -5.99% | $2.24B | |
$91,589,325 | 7 | -6.97% | $2.8B | |
$7,605,533 | 5 | 17.10% | $2.39B | |
$9,900,000 | 1 | -7.19% | $2.54B | |
$5,000,000 | 1 | -22.84% | $2.4B |
| Increased Positions | 124 | +65.26% | 45M | +28.44% |
| Decreased Positions | 77 | -40.53% | 13M | -8.57% |
| New Positions | 50 | New | 8M | New |
| Sold Out Positions | 17 | Sold Out | 4M | Sold Out |
| Total Postitions | 237 | +24.74% | 189M | +19.87% |
| Fmr Llc | $462,799.00 | 14.92% | 31.79M | +12M | +62.1% | 2025-09-30 |
| Vr Adviser, Llc | $191,631.00 | 6.18% | 13.16M | +399,000 | +3.13% | 2025-09-30 |
| Summer Road Llc | $183,160.00 | 5.91% | 12.58M | -1M | -9.42% | 2025-09-30 |
| Deep Track Capital, Lp | $173,732.00 | 5.6% | 11.93M | -2M | -16.53% | 2025-09-30 |
| Blackrock, Inc. | $153,708.00 | 4.96% | 10.56M | +10,458 | +0.1% | 2025-09-30 |
| Avoro Capital Advisors Llc | $149,240.00 | 4.81% | 10.25M | +3M | +38.51% | 2025-09-30 |
| Vanguard Group Inc | $133,417.00 | 4.3% | 9.16M | +771,065 | +9.19% | 2025-09-30 |
| Tcg Crossover Management, Llc | $89,067.00 | 2.87% | 6.12M | +798,084 | +15% | 2025-09-30 |
| Citadel Advisors Llc | $83,047.00 | 2.68% | 5.7M | +817,767 | +16.74% | 2025-09-30 |
| Point72 Asset Management, L.P. | $66,995.00 | 2.16% | 4.6M | +3M | +141.64% | 2025-09-30 |